MVAX 001

Drug Profile

MVAX 001

Alternative Names: MVAX-001

Latest Information Update: 01 Jun 2016

Price : $50

At a glance

  • Originator Institute for Molecular Medicine
  • Developer MolecuVax
  • Class Antineoplastics; Cell therapies; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 09 May 2016 MolecuVax in-licenses patent covering composition of matter from UniVax, LLC
  • 11 Apr 2016 Preclinical trials in Cancer in USA (IV) before April 2016
  • 11 Apr 2016 MolecuVax plans a phase I trial for Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top